Today PAREXEL Consulting (Boston, MA) released its second annual study on the state of the FDA drug review process. Findings are captured in the white paper The Innovation Imperative in the Safety First Era, which answers questions such as:
“The implications of FDAAA and CDER’s implementation of the law have been widely discussed, and there is considerable conjecture in the biopharmaceutical industry regarding how FDA review timelines and the approval process are being impacted by new requirements, such as REMS," said Mark Mathieu, Director of Strategic Research at PAREXEL Consulting and the study’s lead author. "What our research provides is a real-world, metrics-based assessment to help inform expectations of new drug review outcomes in the Safety First Era."
That assessment also includes discussions on real-world implications of overdue NDA reviews on first-cycle approval rates and why priority-rated drugs continue to have advantages in the drug review process, despite their decline.
To find out more, the white paper is available for down load here.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.